Shares of OrthoPediatrics Corp. (NASDAQ:KIDS – Get Free Report) reached a new 52-week high during mid-day trading on Thursday after Needham & Company LLC raised their price target on the stock from $30.00 to $35.00. Needham & Company LLC currently has a buy rating on the stock. OrthoPediatrics traded as high as $23.11 and last traded at $22.81, with a volume of 19242 shares traded. The stock had previously closed at $22.31.
A number of other research analysts have also issued reports on the company. Truist Financial increased their target price on OrthoPediatrics from $17.00 to $20.00 and gave the company a “hold” rating in a research report on Thursday, July 16th. TD Cowen restated a “buy” rating on shares of OrthoPediatrics in a research report on Monday, June 15th. Canaccord Genuity Group set a $25.00 price objective on shares of OrthoPediatrics in a report on Friday, April 24th. Weiss Ratings reiterated a “sell (e+)” rating on shares of OrthoPediatrics in a research report on Friday, July 17th. Finally, BTIG Research reissued a “buy” rating and set a $24.00 target price on shares of OrthoPediatrics in a research note on Friday, May 1st. Nine investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $25.89.
View Our Latest Stock Analysis on KIDS
Institutional Trading of OrthoPediatrics
OrthoPediatrics Stock Up 1.9%
The business has a 50-day moving average of $19.18 and a 200-day moving average of $17.84. The company has a debt-to-equity ratio of 0.29, a quick ratio of 2.37 and a current ratio of 5.21. The stock has a market capitalization of $583.63 million, a price-to-earnings ratio of -13.57 and a beta of 0.98.
OrthoPediatrics (NASDAQ:KIDS – Get Free Report) last posted its earnings results on Tuesday, August 4th. The company reported ($0.26) EPS for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.04. The company had revenue of $70.51 million for the quarter, compared to analysts’ expectations of $68.21 million. OrthoPediatrics had a negative net margin of 15.72% and a negative return on equity of 8.10%. On average, sell-side analysts expect that OrthoPediatrics Corp. will post -1.13 EPS for the current year.
About OrthoPediatrics
OrthoPediatrics Corp., founded in 2007 and headquartered in Warsaw, Indiana, is a medical device company dedicated exclusively to providing orthopedic solutions for children. The company focuses on developing, manufacturing and marketing a broad portfolio of implants and instruments designed to address a wide range of pediatric conditions, including trauma, deformity correction, spine disorders and sports injuries.
The company’s product lines include locking plates and screws for upper and lower extremity reconstruction, intramedullary nails for femur and tibia stabilization, and specialized systems such as the MAGEC Magnetic Growth Rod for treatment of early-onset scoliosis.
Featured Stories
- Five stocks we like better than OrthoPediatrics
- Boeing’s Comeback Is Building Momentum—Is It Real?
- Blueprint for a Banking Fortress: Circle Redraws the Map
- Bed Bath & Beyond Renovates: The Neighborhood Blueprint
- These Outperforming Giants Are Boosting Dividends in 2026, With Yields of Up to 6.6%
Receive News & Ratings for OrthoPediatrics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OrthoPediatrics and related companies with MarketBeat.com's FREE daily email newsletter.
